liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Peculiarities of studying the effects of pathogen reduction technologies on platelets
Linköping University, Department of Clinical and Experimental Medicine, Division of Microbiology and Molecular Medicine. Linköping University, Faculty of Medicine and Health Sciences. Region Östergötland, Center for Diagnostics, Department of Clinical Chemistry.
Johannes Gutenberg University of Mainz, Germany.
CHUL, Canada; University of Laval, Canada.
2016 (English)In: PROTEOMICS - Clinical Applications, ISSN 1862-8346, E-ISSN 1862-8354, Vol. 10, no 8, 805-815 p.Article, review/survey (Refereed) Published
Abstract [en]

The transfusion of platelet concentrates (PCs) is mainly used for treatment of thrombocytopenic, trauma or surgery patients. The integrity and safety of these platelet preparations, however, is compromised by the presence of pathogens, such as viruses, bacteria and parasites. The transfer of allogeneic donor leukocytes contaminating PCs can also potentially cause adverse reactions in recipients. These considerations prompted the development and implementation of pathogen reduction technologies (PRT), which are based on chemically induced cross-linking and inactivation of nucleic acids. While the incumbent PRT may provide some protection against transfusion-transmitted infections, they are ineffective against infectious prions and may not inactivate other emerging pathogens. In addition, the safety of PRT concerning platelet viability and function has been questioned in several reports. Recent studies suggest that PRT, such as Intercept, may adversely affect the messenger RNA (mRNA) and microRNA content of platelets, as well as their functional integrity, which may compromise the clinical benefits of PRT. Here, we will discuss about the peculiarities of studying the effects of PRT on platelets, which will need to be taken into account in future studies aimed to characterize further, and polish, the rugged side of this otherwise useful and potentially important approach in transfusion medicine.

Place, publisher, year, edition, pages
WILEY-V C H VERLAG GMBH , 2016. Vol. 10, no 8, 805-815 p.
Keyword [en]
MicroRNA; Pathogen reduction; Platelet concentrate; Platelet proteomic; Transfusion medicine
National Category
URN: urn:nbn:se:liu:diva-132080DOI: 10.1002/prca.201500124ISI: 000383848400006PubMedID: 27095411OAI: diva2:1038391

Funding Agencies|County Council of Ostergotland, Sweden [LIO-202231, LIO-203061]; Canadian Blood Services/Canadian Institutes of Health Research Blood Utilization and Conservation Initiatives via Health Canada [286777, 327364]

Available from: 2016-10-18 Created: 2016-10-17 Last updated: 2016-10-18

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Osman, Abdimajid
By organisation
Division of Microbiology and Molecular MedicineFaculty of Medicine and Health SciencesDepartment of Clinical Chemistry
In the same journal
PROTEOMICS - Clinical Applications

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 16 hits
ReferencesLink to record
Permanent link

Direct link